Nature Communications (Feb 2023)
Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model
- L. Tanner,
- A. B. Single,
- R. K. V. Bhongir,
- M. Heusel,
- T. Mohanty,
- C. A. Q. Karlsson,
- L. Pan,
- C-M. Clausson,
- J. Bergwik,
- K. Wang,
- C. K. Andersson,
- R. M. Oommen,
- J. S. Erjefält,
- J. Malmström,
- O. Wallner,
- I. Boldogh,
- T. Helleday,
- C. Kalderén,
- A. Egesten
Affiliations
- L. Tanner
- Respiratory Medicine, Allergology, & Palliative Medicine, Department of Clinical Sciences Lund, Lund University and Skåne University Hospital
- A. B. Single
- Respiratory Medicine, Allergology, & Palliative Medicine, Department of Clinical Sciences Lund, Lund University and Skåne University Hospital
- R. K. V. Bhongir
- Respiratory Medicine, Allergology, & Palliative Medicine, Department of Clinical Sciences Lund, Lund University and Skåne University Hospital
- M. Heusel
- Division of Infection Medicine, Department of Clinical Sciences, Lund University
- T. Mohanty
- Division of Infection Medicine, Department of Clinical Sciences, Lund University
- C. A. Q. Karlsson
- Division of Infection Medicine, Department of Clinical Sciences, Lund University
- L. Pan
- Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston
- C-M. Clausson
- Division of Airway Inflammation, Department of Experimental Medical Sciences, Lund University
- J. Bergwik
- Respiratory Medicine, Allergology, & Palliative Medicine, Department of Clinical Sciences Lund, Lund University and Skåne University Hospital
- K. Wang
- Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston
- C. K. Andersson
- Respiratory Cell Biology, Department of Experimental Medical Sciences Lund, Lund University
- R. M. Oommen
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet
- J. S. Erjefält
- Division of Airway Inflammation, Department of Experimental Medical Sciences, Lund University
- J. Malmström
- Division of Infection Medicine, Department of Clinical Sciences, Lund University
- O. Wallner
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet
- I. Boldogh
- Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston
- T. Helleday
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet
- C. Kalderén
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet
- A. Egesten
- Respiratory Medicine, Allergology, & Palliative Medicine, Department of Clinical Sciences Lund, Lund University and Skåne University Hospital
- DOI
- https://doi.org/10.1038/s41467-023-36314-5
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 16
Abstract
Idiopathic pulmonary fibrosis is a disease caused by persistent micro-injuries to the lung ultimately resulting in death. Here, the authors describe the use of a small molecule OGG1 inhibitor, TH5487, as a potent and potentially clinically relevant treatment for IPF.
